Oligonucleotide Pool Market Size, Business Revenue Forecast, Leading Competitors and Growth Trends 2027
Oligonucleotide pool market is driven by three major factors
such as huge investments from big pharmaceutical companies in oligonucleotide
therapeutics for drug development, CMO’s involvement in manufacturing therapeutic
oligonucleotides and wide application areas offered by the oligonucleotides.
It has been noted that global oligonucleotide
pool market is growing at moderate pace and is expected to grow at the CAGR
of 8.5%.There are only small number of approved oligonucleotide drugs available
in the market. Currently there are only three drugs available in the U.S.
Having said that, according to Nitto Denko Avecia internal research, nearly 116
oligonucleotides were in active clinical trials as of August 2015. Very few of
the oligonucleotide drug sponsors have their own in-house cGMP manufacturing
facilities.
Request
Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2556
On the other hand, more than half of the oligonucleotides in
the clinical development stage are manufactured by the contract manufacturing
organizations (CMO). As more number of oligonucleotides are on the verge of
regulatory approval, the demand for such oligonucleotides will increase in the
market. The increased demand is likely to force the CMO’s to increase their
capacity and improve efficiency in manufacturing the oligonucleotides. CMO’s
are adopting different strategies to increase the manufacturing capacity. For
example, in 2014, German CMO BioSpring added a midscale synthesizer to increase
the capacity. Nitto Denko Avecia, the leading CMO has implemented the use of
thin film evaporation in order to concentrate product solutions prior to
lyophilisation which results in larger final batches of custom oligos. The
increasing involvement of the CMOs in order to cater to the demand of
oligonucleotides is likely to boost the growth of the oligonucleotide pool
market.
Global Oligonucleotide Pool Market - Competitive Analysis
February, 2017 - Integrated DNA Technologies, Inc. had
announced the acquisition of oligo manufacturing business of GeneWorks
(Australia). This acquisition by the company enhances the capacity for direct
sales of genomic products in Asia-Pacific region. Integrated DNA Technologies,
Inc. (IDT) is one of the leading biotechnology company that is involved in
manufacturing, developing nucleic acid products for the life sciences industry.
The company mainly sells and distributes short strands of DNA called
oligonucleotides. The company’s essential business is the creation of custom
oligonucleotides for molecular biology applications. IDT has created
restrictive innovations for genomics applications, which include generation
sequencing, CRISPR genome editing, qPCR, and RNA interference. The products
offered by the company serves many of the small university academic research,
biotechnology, clinical diagnostics, and pharmaceutical development all around
the world. The company is specialized in Custom Oligonucleotides, DNA
Synthesis, Synthetic Biology, RNA Synthesis, Synthesis Reagents, Next
generation sequencing, Nucleic Acid Synthesis, Genes & gene fragments,
Primers, GMP Manufacturing, Genotyping, Probes, RNAi, qPCR, and CRISPR genome
editing.
December, 2016 – Agilent Company announced the acquisition
of Multiplicom N.V., a Leading European Diagnostics Company. On this
acquisition Herman Verrelst, vice president said “The acquisition of
Multiplicom significantly strengthens our presence in the genomics
market". Agilent is one of the leaders in life sciences, diagnostics and
applied chemical markets. The company provides services to laboratories all around
the world with its instruments, services, consumables, applications and
expertise. Agilent mainly focuses on six major industries which involve food,
environmental and forensics, pharmaceutical, diagnostics, chemical and energy
and research. The company with its three brands CrossLab combines, Dako Agilent
Pathology Solutions and Agilent OpenLAB Software Suite is innovating and
providing special services to laboratories with high technology.
Global Oligonucleotide Pool Market - Regional Analysis
As per Market Research Future analysis, the global
oligonucleotide pool market has grown tremendously in Asia-Pacific.
Geographically, North America holds the largest share of more than 42.2% of
oligonucleotide pool market and is expected to be the leading market during
2016-2022. The major factor that influences the growth of the North American
oligonucleotide pool market is the existence of large number of small scale and
big scale manufacturers of oligonucleotide pool and service providers in the
region.
After North America region, Europe market is the second
largest market in the global oligonucleotide pool market. Increasing investment
by organizations in the field of genomics serves as a significant driver for
this region. Whereas Asia Pacific region is expected to be the fastest growing
market due to increasing R&D funding by the developing countries like China
and India for the development of oligonucleotide products.
Browse Detailed TOC
with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/oligonucleotide-pool-market-2556
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Comments
Post a Comment